# Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

> **NCT04107727** · PHASE2 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 273 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Quizartinib
- **DRUG:** Placebo oral tablet
- **DRUG:** Cytarabine
- **DRUG:** Idarubicin

## Key facts

- **NCT ID:** NCT04107727
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-05
- **Primary completion:** 2024-10-03
- **Final completion:** 2025-01-24
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04107727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04107727, "Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04107727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*